Lilly's retatrutide shows sweeping obesity and cardiometabolic benefits in Phase 3 trials
TL;DR Summary
Lilly revealed that retatrutide, a once‑weekly GIP/GLP‑1/glucagon triple agonist, produced major weight loss (up to 70.3 lbs, 28.3% at 80 weeks) and strong A1C reductions (up to 2.0%) in Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1, plus meaningful knee osteoarthritis pain and sleep apnea improvements, suggesting potential to treat obesity and its related complications; results were presented at the ADA 86th Scientific Sessions and published in The Lancet.
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com
- Lilly shares safety, tolerability data on its next-gen obesity drug statnews.com
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters
- A new wave of weight-loss therapies aims to be better than today’s GLP-1s MarketWatch
- ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
23 min
vs 24 min read
Condensed
99%
4,659 → 66 words
Want the full story? Read the original article
Read on investor.lilly.com